Literature DB >> 10098784

Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group.

M Connolly1, N Noah.   

Abstract

A surveillance system to assess the impact and changing epidemiology of invasive meningococcal disease in Europe was set up in 1987. Since about 1991, contributors from national reference laboratories, national communicable disease surveillance centres and institutes of public health in 35 European countries provided information on all reported cases of meningococcal disease in their country. We describe some trends observed over the period 1993-6. The main findings were: the overall incidence of meningococcal disease was 1.1 per 100000 population but there was some evidence of a slow increase over time and with northern European countries tending to have a higher incidence (Kendall correlation 0.5772, P < 0.001), an increasing predominance of serogroup C, and a shift in the age distribution towards teenagers and away from younger children (chi2 test for trend 44.56, P < 0.0001), although about half of the cases were under 5 years of age. The overall case fatality rate was 8.3% and the most common serosubtypes were B:15:P1.7,16 and C:2a:P1.2,5.

Entities:  

Mesh:

Year:  1999        PMID: 10098784      PMCID: PMC2809586          DOI: 10.1017/s0950268898001848

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  29 in total

1.  Laboratory confirmation of meningococcal disease in Scotland, 1993-9.

Authors:  S C Clarke; J Reid; L Thom; B C Denham; G F S Edwards
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

2.  Evaluation of a fluorescence-based PCR method for identification of serogroup a meningococci.

Authors:  M A Diggle; K Smith; E K Girvan; S C Clarke
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

3.  A 20-year ecological study of the temporal association between influenza and meningococcal disease.

Authors:  Elise Snitker Jensen; Søren Lundbye-Christensen; Susanne Samuelsson; Henrik Toft Sørensen; Henrik Carl Schønheyder
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

4.  Structural bioinformatics of Neisseria meningitidis LD-carboxypeptidase: implications for substrate binding and specificity.

Authors:  Yasmeen Rashid; M Kamran Azim
Journal:  Protein J       Date:  2011-12       Impact factor: 2.371

5.  Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Authors:  Ingeborg S Aaberge; Philipp Oster; Oddveig S Helland; Anne-Cathrine Kristoffersen; Ellen Ypma; E Arne Høiby; Berit Feiring; Hanne Nøkleby
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

6.  Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada.

Authors:  Raymond S W Tsang; Averil M Henderson; Marissa L Cameron; Shaun D Tyler; Shari Tyson; Dennis K S Law; Jan Stoltz; Wendell D Zollinger
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

7.  Transcriptome analysis of Neisseria meningitidis during infection.

Authors:  Guido Dietrich; Sebastian Kurz; Claudia Hübner; Christian Aepinus; Stephanie Theiss; Matthias Guckenberger; Ursula Panzner; Jacqueline Weber; Matthias Frosch
Journal:  J Bacteriol       Date:  2003-01       Impact factor: 3.490

8.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Meningococcal disease in South Africa, 1999-2002.

Authors:  Garry B Coulson; Anne von Gottberg; Mignon du Plessis; Anthony M Smith; Linda de Gouveia; Keith P Klugman
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.